专利检索_ .作用于酸酐;涉及细胞和亚细胞运动专利检索_ .作用于酸酐;涉及细胞和亚细胞运动专利检索查询

子分类：

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
1	用于生产重组蛋白质的方法	CN201380055655.2	2013-09-30	CN104781405A	2015-07-15	K·L·凯恩
本发明公开涉及使用NHEJ蛋白质或其功能片段、或者编码它们的多核苷酸转染的宿主细胞，其中所述的多核苷酸序列处于合适的启动子的控制之下，并且所述的宿主细胞还被表达盒转染，所述的表达盒包含编码至少一种目的蛋白质的多核苷酸序列，本发明公开还涉及制备宿主细胞、质粒以及在制备宿主细胞和质粒过程中使用的中间体的方法，以及宿主细胞表达蛋白质的用途。
2	P97-抗体缀合物和使用方法	CN201280040630.0	2012-07-05	CN103747807A	2014-04-23	罗布·哈特奇森; 蒂莫西·Z·维塔利斯; 瑞恩哈德·加巴斯勒尔
本发明提供了p97-抗体缀合物以及相关的组合物和方法，这些缀合物、组合物和方法可以用于多种治疗方法中的任何一种，包括用于治疗癌症如表达Her2/neu的癌症和表达Her1/EGFR的癌症的方法。
3	P97-抗体缀合物和使用方法	CN201280040630.0	2012-07-05	CN103747807B	2016-12-07	罗布·哈特奇森; 蒂莫西·Z·维塔利斯; 瑞恩哈德·加巴斯勒尔
本发明提供了p97-抗体缀合物以及相关的组合物和方法，这些缀合物、组合物和方法可以用于多种治疗方法中的任何一种，包括用于治疗癌症如表达Her2/neu的癌症和表达Her1/EGFR的癌症的方法。
4	卵巢癌生物标志物	CN201480050482.X	2014-09-17	CN105531590A	2016-04-27	A·J·布特; L·A·绍博; P·卡特里; B·X·林
提供生物标志物和生物标志物组，用于进行卵巢癌评估，例如，诊断卵巢癌、预测卵巢癌对卵巢癌治疗的反应性以及监测卵巢癌。可进一步根据分类对患者进行治疗。还提供使用这些生物标志物进行卵巢癌评估的方法、试剂、装置和试剂盒。
5	酵素構築物	JP2015522172	2013-07-18	JP6429773B2	2018-11-28	ヘロン,アンドリュー; クラーク,ジェームス; モイセイ,ルース; ウォレス,エリザベスジェーン; ブルース,マーク; ジャヤシンゲ,ラクマル; カプロッティ,ドメニコ; ソエロエス,サボルチ; マクニール,ルーク; ミッシャ,ミハエラ

6	Role of a cluster of long noncoding RNA transcripts in protecting the heart from pathological hypertrophy	US14884827	2015-10-16	US09844583B2	2017-12-19	Ching-Pin Chang
Nucleic acids encoding modified myosin heavy-chain-associated RNA transcripts are provided. The modified myosin heavy-chain-associated RNA transcripts belongs to a cluster of long noncoding RNAs (lncRNA) and bind to chromatin remodeler Brg1 to inhibit Brg1's genomic targeting and gene regulation function. The modified myosin heavy-chain-associated RNA transcripts expressed in an individual inhibit Brg1's gene regulation function and protect the heart of the individual from myopathy and failure. One of the modified heavy-chain-associated RNAs is a 400 base pair fragment segmented from a natural 779 base pair sequence of Mhrt (Mhrt779) and has the same cardioprotective effects as the Mhrt779.
7	Enzyme construct	US14415533	2013-07-18	US09797009B2	2017-10-24	Andrew Heron; James Clarke; Ruth Moysey; Elizabeth Jayne Wallace; Mark Bruce; Lakmal Jayasinghe; Domenico Caprotti; Szabolcs Soeroes; Luke McNeill; Mihaela Misca
The invention relates to methods using constructs comprising a helicase and an additional polynucleotide binding moiety. The helicase is attached to the polynucleotide binding moiety and the construct has the ability to control the movement of a polynucleotide. The constructs can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides.
8	KIF20A epitope peptides for TH1 cells and vaccines containing the same	US14413403	2013-07-09	US09561265B2	2017-02-07	Yasuharu Nishimura; Yusuke Tomita; Ryuji Osawa
Isolated KIF20A-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce KIF20A-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.
9	P97-ANTIBODY CONJUGATES AND METHODS OF USE	US14837662	2015-08-27	US20160053237A1	2016-02-25	Wilfred Jefferies; Timothy Z. Vitalis; Reinhard Gabathuler
The present invention provides p97-antibody conjugates and related compositions and methods, which may be used in any of a variety of therapeutic methods, including methods for the treatment of cancers such as Her2/neu-expressing and Her1/EGFR-expressing cancers.
10	P97-antibody conjugates and methods of use	US13542435	2012-07-05	US09150846B2	2015-10-06	Wilfred Jefferies; Timothy Z. Vitalis; Reinhard Gabathuler
The present invention provides p97-antibody conjugates and related compositions and methods, which may be used in any of a variety of therapeutic methods, including methods for the treatment of cancers such as Her2/neu-expressing and Her1/EGFR-expressing cancers.
11	ENZYME CONSTRUCT	US15704395	2017-09-14	US20180230526A1	2018-08-16	Andrew John Heron; James Anthony Clarke; Ruth Moysey; Elizabeth Jayne Wallace; Mark Bruce; Lakmal Jayasinghe; Domenico Caprotti; Szabolcs Soeroes; Luke McNeill; Mihaela Misca
The invention relates to methods using constructs comprising a helicase and an additional polynucleotide binding moiety. The helicase is attached to the polynucleotide binding moiety and the construct has the ability to control the movement of a polynucleotide. The constructs can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides.
12	CRYSTAL STRUCTURES OF HUMAN TORSIN-A AND METHODS OF DETERMINING AND USING THE SAME	US15442639	2017-02-25	US20170248601A1	2017-08-31	Thomas U. Schwartz; F. Esra Demircioglu; Brian A. Sosa-Alvarado
A protein composition including TorsinA or TorsinA mutant, LULL1, and a nanobody obtained by immunization using TorsinA and LULL1 is used to grow complex crystals, and three dimensional structures are determined using x-ray data of the crystals. A creening platform is built based on the determined three dimensional structures for designing a drug lead to cure dystonia.
13	KIF20A Epitope Peptides for TH1 Cells and Vaccines Containing the Same	US15385141	2016-12-20	US20170196956A1	2017-07-13	Yasuharu Nishimura; Yusuke Tomita; Ryuji Osawa
Isolated KIF20A-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce KIF20A-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.
14	ROLE OF A CLUSTER OF LONG NONCODING RNA TRANSCRIPTS IN PROTECTING THE HEART FROM PATHOLOGICAL HYPERTROPHY	US14884827	2015-10-16	US20160114004A1	2016-04-28	Ching-Pin CHANG
Nucleic acids encoding modified myosin heavy-chain-associated RNA transcripts are provided. The modified myosin heavy-chain-associated RNA transcripts belongs to a cluster of long noncoding RNAs (lncRNA) and bind to chromatin remodeler Brg1 to inhibit Brg1's genomic targeting and gene regulation function. The modified myosin heavy-chain-associated RNA transcripts expressed in an individual inhibit Brg1's gene regulation function and protect the heart of the individual from myopathy and failure. One of the modified heavy-chain-associated RNAs is a 400 base pair fragment segmented from a natural 779 base pair sequence of Mhrt (Mhrt779) and has the same cardioprotective effects as the Mhrt779.
15	KIF20A EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING THE SAME	US14413403	2013-07-09	US20150190489A1	2015-07-09	Yasuharu Nishimura; Yusuke Tomita; Ryuji Osawa
Isolated KIF20A-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce KIF20A-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.
16	P97-antibody conjugates and methods of use	US14837662	2015-08-27	US09850472B2	2017-12-26	Timothy Z. Vitalis; Reinhard Gabathuler
The present invention provides p97-antibody conjugates and related compositions and methods, which may be used in any of a variety of therapeutic methods, including methods for the treatment of cancers such as Her2/neu-expressing and Her1/EGFR-expressing cancers.
17	Crystal structures of human Torsin-A and methods of determining and using the same	US15442639	2017-02-25	US09823250B2	2017-11-21	Thomas U. Schwartz; F. Esra Demircioglu; Brian A. Sosa-Alvarado
A protein composition including TorsinA or TorsinA mutant, LULL1, and a nanobody obtained by immunization using TorsinA and LULL1 is used to grow complex crystals, and three dimensional structures are determined using x-ray data of the crystals. A screening platform is built based on the determined three dimensional structures for designing a drug lead to cure dystonia.
18	Biomarkers for Ovarian Cancer	US14914245	2014-09-17	US20160291024A1	2016-10-06	Atul J. Butte; Linda Anne Szabo; Purvesh Khatri; Bruce Xuefeng Ling
Biomarkers and biomarker panels are provided for making ovarian cancer assessments, for example, diagnosing an ovarian cancer, predicting responsiveness of an ovarian cancer to an ovarian cancer therapy, and monitoring an ovarian cancer. A patient may further be treated in accordance with the classification. Also provided are methods, reagents, devices and kits for the use of these biomarkers in making ovarian cancer assessments.
19	Methods for Producing Recombinant Proteins	US14431855	2013-09-30	US20150252385A1	2015-09-10	Katharine Lacy Cain
The present disclosure relates to a host cell transfected with a NHEJ protein or a functional fragment thereof or a polynucleotide encoding the same, wherein said polynucleotide sequence is under the control of a suitable promoter and the host cell is also transfected with an expression cassette comprising a polynucleotide sequence encoding at least one protein of interest, methods of preparing the host cells, plasmids and intermediates employed in the preparation of the same and use of the host cells to express to protein.
20	ENZYME CONSTRUCT	US14415533	2013-07-18	US20150218629A1	2015-08-06	Andrew Heron; James Clarke; Ruth Moysey; Elizabeth Jayne Wallace; Mark Bruce; Lakmal Jayasinghe; Domenico Caprotti; Szabolcs Soeroes; Luke McNeill; Mihaela Misca
The invention relates to methods using constructs comprising a helicase and an additional polynucleotide binding moiety. The helicase is attached to the polynucleotide binding moiety and the construct has the ability to control the movement of a polynucleotide. The constructs can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides.

1 2

该功能需要专业版企业版VIP权限，您可以：